Efficacy and Safety of Adapalene Gel 0.3% vs Differin® in Acne Vulgaris

Phase 3, randomised, double-blind trial of adapalene in acne vulgaris (3 arms), sponsored by Aleor Dermaceuticals Limited. Primary endpoints: Mean percent change from baseline in inflammatory lesion counts at 12 weeks and Mean percent change from baseline in non-inflammatory lesion counts at 12 weeks. Started Sep 2018; status: completed.